Background: Continuous levodopa-carbidopa intestinal gel (LCIG) diminishes daily
| INTRODUCTION
Patients with advanced Parkinson's disease (PD) suffer from daily motor fluctuations and dyskinesia. "On" time means periods of good motor control with no disturbing dyskinesia, while "off" time is periods of stiffness and poor mobility. Ideal medication reduces "off" time and minimizes dyskinesia. Combinations of levodopa with carbidopa or benserazide, dopamine agonists, MAO-B inhibitors and COMT inhibitors are the standard treatment for PD (Horstink et al., 2006) . In the advanced disease state, wearing off, on-off phases, or dyskinesia lead to functional impairment (Ahlskog & Muenter, 2001 ). The short half-life of oral levodopa and individual variation of gastric emptying in PD patients cause daily fluctuations in levodopa plasma concentration. Deep brain stimulation (DBS) (Deep Brain Stimulation for Parkinson's Disease Study, Group, 2001) , apomorphine infusion (Trenkwalder et al., 2015) and continuous infusion of levodopa-carbidopa intestinal gel (LCIG) (Nilsson, Nyholm, & Aquilonius, 2001 ) are device-aided therapies that can diminish "off" -time and dyskinesia in advanced PD. DBS, LCIG and an apomorphine pump are considered only if a combinations of the aforementioned oral drugs is not sufficient. In Finland DBS has been available since 1995, and LCIG since 2006 with 100% reimbursement.
Apomorphine pump has been available in Finland since April 2017.
Levodopa-carbidopa intestinal gel with a levodopa concentration of 20 mg/ml is administered via a portable pump that is connected to the PEG-J, a percutaneous endoscopic gastrostomy (PEG) with a thinner inner J-tube placed in the proximal jejunum. LCIG treatment ensures continuous dopaminergic stimulation and it significantly reduces daily motor fluctuations and dyskinesia compared to oral levodopa (Olanow et al., 2014) . However, complications with the tube or the pump are common, presenting in 40%-96% of patients (Devos, 2009; Fernandez et al., 2013 Fernandez et al., , 2015 Nyholm et al., 2008; Pickut, van der Linden, Dethy, Van De Maele, & de Beyl, 2014) .
The aim of the present study was to analyze the outcome of longterm LCIG treatment in advanced PD, paying special attention to complications and discontinuation of the treatment in the clinical setting.
| PATIENTS AND METHODS
Altogether, 60 patients with advanced PD received LCIG therapy at Helsinki University Hospital between 2006 and 2014. A neurologist selected candidates for LCIG treatment i.e., patients who reported substantial daily motor fluctuations and dyskinesia that could not be sufficiently controlled with oral PD medication. Severe dementia, ongoing psychosis, and unresponsiveness to levodopa were exclusion criteria. The total daily oral doses of levodopa, amantadine, dopamine agonists and MAO-B-and COMT-inhibitors were converted to a morning dose and continuous daily infusion of LCIG. To assess the response to LCIG, the patients were admitted to neurological ward and had a nasojejunal tube (Flocare Bengmark ® 10Fr, Nutricia, Netherlands) for 4-6 days of testing. A radiologist positioned the tube near the ligamentum of Treitz under fluoroscopic control. LCIG was administered with a pump via the nasojejunal tube, and the response to LCIG was assessed with diaries. If this testing phase was successful, the patient had a PEG-J.
| PEG-J procedure
A PEG-J tube (Freka  ® 15 Fr or 20 Fr PEG -tube and Freka  ® 9 Fr in- testinal Tube, Fresenius Kabi, Cheshire, UK) was inserted under endoscopic and fluoroscopic control by gastroenterologic surgeons in the endoscopic unit using the pull-through method (Gauderer, Ponsky, & Izant, 1980) . Antibiotic prophylaxis (1.5 g cefuroxime, Zinacef ® , GlaxoSmithKline, Espoo, Finland) and local anesthesia with lidocaine (10 mg/ml Lidocain ® , Orion, Espoo, Finland) were administered, and conscious sedation was provided by an anesthesiologist. After placement of the PEG tube, the inner J tube was moved near the ligamentum of Treitz with rat-tooth forceps. If this failed, a guidewire (Jagwire, Boston Scientific, Alajuela, Costa Rica) and a triple lumen balloon were passed to the duodenum, the balloon was retrieved and the J tube 
| LCIG infusion in practice
The LCIG (20 mg/ml of levodopa and 5 mg/ml carbidopa; Duodopa ® , Abbvie) dose optimization was carried out in the neurologic ward.
All oral PD medication was usually stopped, with the exception of high-dose dopamine agonists with positive clinical response. The morning bolus was followed by a continuous infusion. Additional doses were administered by the patient when they felt they were entering an "off" phase. Usually, infusion lasted 16 hr, supplemented with a sustained-release oral dose of levodopa for the night. If necessary, night infusion was applied, with the infusion rate being about 40%-60% less than infusion during the day. Control phone calls were planned for 2-4 weeks after and control visits for 6 months after initiation of LCIG for clinical evaluation in the outpatient clinic.
The patients were advised to gradually increase the daily infusion if several extra doses had to be taken daily. In cases of inner tube problems, the patients were advised to administer LCIG via PEG to the gastric space or to restart oral medication. If an infusion problem occurred, a scheduled admission to the neurological ward was arranged, with a subsequent endoscopic procedure to correct the tube problem.
| Data collection at baseline and during the follow-up
The following data were collected: duration of PD, age at onset of 
| Informed consent statement
The study was approved by the hospital ethics committee. Data extraction occurred retrospectively from hospital medical records.
According to Finnish law, retrospective research using hospital medical files does not require informed consent from the study subjects.
| Statistics
The results are reported as means and standard deviation (SD). The significance of differences in categorical data was determined using
Fisher's exact test. The Mann-Whitney U test was used to discover the differences in continuous variables. A level of p < .05 was regarded as statistically significant, and two tailed tests were used.
Statistical calculations were generated using IBM SPSS Statistics 21
(International Business Machines Corporation, Endicott, NY, USA).
| RESULTS
Mean age at onset of PD was 56 (8) years, and the duration of PD was 11 (4) years before LCIG treatment. There were 32 men (53%) and 28 women (47%) with a mean age of 68 (7) years, and 27 participants (45%) were 70 or older. Baseline characteristics are presented in Table 2 .
| LCIG dose
After discharge, 51 patients (85%) had daily LCIG infusion, and nine cases (15%) were 24 hr a day. The mean daily LCIG dose was 1,651
(595) mg. At 6 months, 42 patients (78%) had daily infusion and 12 (22%) had 24-hr infusion. In most cases (44), the LEDD had increased by 505 (304) mg compared with the baseline. In nine patients, the LEDD had decreased by 255 (126) At the end of the follow-up period of 33 (24) months, 38 patients (63%) were on LCIG, 7 (12%) had been on LCIG until death, 13 (22%)
had discontinued LCIG and were alive, and two patients (3%) discontinued LCIG and died later. Thirty-two patients were on LCIG for more than 2 years, and 12 patients for more than 4 years. Fifty-three patients (90%) felt that LCIG treatment still substantially alleviated motor symptoms, when questioned at 6 months and beyond.
T A B L E 1 Baseline characteristics of PD patients on LCIG treatment

| Changes in weight, living conditions and need for walking devices during LCIG treatment
At baseline, the mean BMI of the patients was 24.7 (4.2) kg/m 2 : only three patients (5%) were underweight, 31 (57%) were normal weight and 26 (43%) were overweight. At the end of the follow-up, eight patients (13%) were underweight, 31 (52%) were normal weight and 21 (35%) were overweight. The weight change as a percentage was −3.3% (10.7%) in 25.7 (23.1) months. Eighteen patients (30%) had weight loss of ≥5%, and in 12 patients (20%), weight loss was ≥10%.
One patient had fatal weight loss despite discontinuation of LCIG.
Body CT did not show any malignancy. The autopsy failed to reveal any clear cause for his deterioration. Two patients had peripheral neuropathy prior to LCIG, probably due to diabetes and spinal stenosis.
At the end of the follow-up, 38 patients (66%) were still living at home with their spouse or alone, 17 (29%) were in institutional care, (mainly sheltered housing with 24-hr assistance), and three patients had intervals at home and in institutions. Nine patients originally living with their spouse (21%) and four originally living alone (33%) had moved to sheltered housing. The need to use a walker increased by 40%, (n = 21, 37%) and a wheelchair by 50% (n = 6; 11%), and two patients became bedridden.
| Discontinuation
Cognitive decline or dementia at the baseline or appearance of these symptoms during follow up were the most common causes of infusion withdrawal, occurring in seven patients after 27 (25) months of LCIG. In two bedridden patients living in institutions, LCIG was stopped after 38 (12) months. One patient was suffering from stoma problems and discontinued the treatment at 19 months. Two patients (3.3%) stopped LCIG after 3 months and 5 months because of inefficacy. One patient subjectively felt dizziness during LCIG treatment and decided to discontinue the LCIG infusion after a month, although clinical examination showed no signs of either postural instability or orthostatic hypotension. Altogether, after a mean of 21 (21) months, LCIG was discontinued in 15 patients, and in 11 cases the reason was recurrent removal of the inner tube by the patient.
| Complications
Sixty patients underwent a total of 156 endoscopic procedures. An additional 96 endoscopic procedures following 60 PEG-J placements are presented in Table 3 , and complications related to LCIG treatment are shown in Table 4 . There were 48 patients (80%) with a total of 143 complications, and only 12 patients with no complications. occurred significantly more often in patients with cognitive decline (MMSE <24), than in those without it: 8 (73%) vs. 12 (35%); p = .034.
There were no peritonitis cases during the follow-up.
| Mortality
According to death certificates provided by Statistics Finland, there were no PEG-J related complications or deaths. Altogether, nine patients died, seven of whom were on LCIG until death. Two patients died 3.7 and 21.5 months after discontinuing LCIG, respectively.
The time from the start of LCIG to death was 26.6 (14) months. The causes of death were defined by clinical examination in four patients and by clinical autopsy in five patients. The immediate causes of death were pneumonia (n = 4), advanced PD (n = 2), coronary heart disease or insufficiency (n = 2) and pulmonary embolism (n = 1). The underlying causes of death were PD (n = 7) and coronary heart disease (n = 2).
Body mass index at onset was significantly higher in those alive at the end of the follow-up compared to those who died: 25.1(4.4) vs.
22.2(3.4); p = .043. Similarly, BMI at the latest follow-up visit was significantly higher in those alive at the end of the follow-up than in those who died during the follow-up, at 24.3 (4.0) vs. 18.9 (3.1); p = .001.
Four underweight patients (44%) died, compared to five patients (8%) with normal weight or overweight; p = .013.
| DISCUSSION
Levodopa-carbidopa intestinal gel treatment has proved to be effective in reducing levodopa-related dyskinesia and diminishing off time compared to oral medication, leading to improvement in the quality of life (Antonini, Yegin, Preda, Bergmann, & Poewe, 2015; Lopiano et al., 2016; Olanow et al., 2014; Wirdefeldt, Odin, & Nyholm, 2016 ).
We present data on LCIG therapy, focusing on complications. The majority of our patients were satisfied with the infusion during followup. There were, however, numerous tube and stoma complications related to LCIG, as reported previously (Fernandez et al., 2015; Lang et al., 2016; Nilsson et al., 2001 ).
In most of our patients, LEDD was increased at 6 months compared to baseline. The LEDD increase may be caused by disease progression. We had 12 patients (20%) with their LCIG pump running for 24 hr. That is slightly more than previously reported by Devos et al.
(10% LCIG for 24 hr) (Devos, 2009) . One study showed a quite stable LEDD on LCIG for 12 months (Antonini et al., 2015) .
In some studies, dementia was an exclusion criterion, and only patients with an MMSE of 28-29 were included (Epstein et al., 2016; Fernandez et al., 2015) . In a French multicentre study (Devos, 2009) Despite the LCIG treatment, 29% of our patients were in institutional care, mainly sheltered housing with 24-hr assistance at the end of the follow-up.
Several technical problems and complications increase the annual admission rate and contact with the hospital (Nyholm et al., 2008) .
Complications with the PEG-J tube (Devos, 2009; Fernandez et al., 2013; Nyholm et al., 2008) are similar to complications related to PEG for feeding purposes (Schapiro & Edmundowicz, 1996; Udd et al., 2015) . The risk of peritonitis has varied between zero and 4% (Devos, 2009; Epstein et al., 2016; Lang et al., 2016; Palhagen et al., 2016) , and other serious complications like colonic perforations, gastropleural fistula (Klostermann et al., 2012) and liver injury (Pickut et al., 2014 ), have also been described. In our material, we did not have any peritonitis, nor any need for emergency abdominal surgery due to LCIG complications. A peristomal infection risk of 8% is comparable with the literature: 10%-20% (Devos, 2009; Epstein et al., 2016; Fernandez et al., 2015; Olanow et al., 2014) . Inner tube complications were mostly accidental removal, kinking or dislocation of the tube occurring during the LCIG treatment in physically active patients, sometimes suffering from disorientation (Devos, 2009; Fernandez et al., 2013; Nyholm et al., 2008; Pickut et al., 2014) . We did not find any cases of inner tube-induced duodenal decubitus ulcer (Martino et al., 2016) , or bezoar sometimes present in these patients. Our results showed that 13 patients had a total of 27 tube occlusions, and eight of them (61%) had altogether ten knots in the inner tube. Previously, only three case reports of five patients with knotting of the inner tube had been published (del-Hoyo-Francisco et al., 2015; Krones, Zollner, & Petritsch, 2012; Nyholm et al., 2008) . The Freka ® intestinal tube has an angled, C-shaped tip, and this may predispose the tube to knots (Figure 1 ). The present results showing that removal of the inner tube occurs more often in patients with dementia are supported by previous findings (Devos, 2009) . Logically, among patients with no dementia, the rate is lower (Epstein et al., 2016; Fernandez et al., 2015) .
The triangular external fixation plate of the Freka ® PEG-J tube is suboptimal, because it glides along the PEG tube, allowing the PEG to move back and forth. This movement may even predispose the patient F I G U R E 1 Naive and knotted jejunal tube to peritonitis in the first days when the stoma is maturing (Epstein et al., 2016) . The skin around the peristomal area may become irritated by leaking gastric fluids. Granulation formation needs referral to a stoma nurse. Granulation tissue was more common in our patients (35%) compared to other series (20%-22%) (Epstein et al., 2016; Lang et al., 2016) .
Weight loss is an adverse event increasing the risk of death, and is partly associated with the natural course of PD. One third of our patients had ≥5% weight loss during the follow-up with one fatal weight loss despite discontinuation of LCIG. Decreased weight has been observed in 5%-10% of LCIG patients (Antonini et al., 2015; Merola et al., 2016) . The mechanism for weight loss in LCIG remains ambiguous. Monitoring weight during LCIG treatment is essential to avoid serious weight loss.
Eighty percent of the patients had complications leading to multiple endoscopic procedures, but still 90% were satisfied with the treatment. Some of the complications may therefore be related to the suboptimal devices and tubes. A new T-port was found to be well tolerated, and it had a low number of tube problems, but proper cleaning and local treatment of the stoma site were necessary (van Laar, Nyholm, & Nyman, 2016) . The use of a T-port is not widely spread, though.
Currently, there are no guidelines for withdrawal of LCIG. If the patient is bedridden, disoriented and already needs maximal care, LCIG probably may not give any significant health benefit. Several removals of the inner tube by a patient during the treatment suggest that the mental condition of that patient has significantly deteriorated. In these cases, discontinuation of LCIG should be individually considered. Further, several replacements of the inner tube increase the burden of already limited hospital resources. Continuous weight loss can even be a fatal complication, and therefore needs monitoring. Close co-operation between neurological and endoscopic units is required, and units must be prepared for common and recurrent PEG-J problems when LCIG treatment for advanced PD is carried out.
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